Garry M Walsh gained his PhD (1992) from National Heart & Lung Institute, University of London, U.K. His work on the pathogenesis of respiratory and allergic disease spans 30-years with an emphasis on the role played by airway epithelial cells and eosinophils. He has over 160 peer-reviewed articles, invited editorials, reviews and book chapters. His publications have been cited over 3,800 times (h-index 37) and has been an invited speaker and/or chairman at over fifty international meetings. He is the Editor-in-Chief of Therapeutics and Clinical Risk Management; Clinical Medicine: Therapeutics, and the Journal of Cell Death and also a member of the editorial boards of 16 further journals. Garry M Walsh gained his PhD (1992) from National Heart & Lung Institute, University of London, U.K. His work on the pathogenesis of respiratory and allergic disease spans 30-years with an emphasis on the role played by airway epithelial cells and eosinophils. He has over 160 peer-reviewed articles, invited editorials, reviews and book chapters. His publications have been cited over 3,800 times (h-index 37) and has been an invited speaker and/or chairman at over fifty international meetings. He is the Editor-in-Chief of Therapeutics and Clinical Risk Management; Clinical Medicine: Therapeutics, and the Journal of Cell Death and also a member of the editorial boards of 16 further journals.

Immunology